Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer

S. M. Swain, S. Steinberg, Marc E Lippman

Research output: Contribution to journalArticle

Abstract

Twenty-six patients (25 evaluable for response) with previously treated metastatic breast cancer were treated with intermediate-dose methotrexate (300 mg/m2) followed by 5-fluorouracil (600 mg/m2) and folinic acid-SF (Leucovorin) rescue (10 mg/m2 q 6 h x 6 doses) with or without tamoxifen (20 mg) and conjugated estrogen (Premarin) (.625 mg twice daily) depending on receptor status. There were two partial responses (8%) with no difference in response between patients who did or did not receive hormones. Toxicity was primarily hematological and elevation of liver function tests. The above schedule has minimal activity in previously treated metastatic breast-cancer patients.

Original languageEnglish
Pages (from-to)445-447
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number4
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Salvage Therapy
Methotrexate
Fluorouracil
Conjugated (USP) Estrogens
Leucovorin
Breast Neoplasms
Liver Function Tests
Tamoxifen
Appointments and Schedules
Hormones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer. / Swain, S. M.; Steinberg, S.; Lippman, Marc E.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 11, No. 4, 01.01.1988, p. 445-447.

Research output: Contribution to journalArticle

@article{057fbf3c29d447ac98e8f50c349ad70c,
title = "Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer",
abstract = "Twenty-six patients (25 evaluable for response) with previously treated metastatic breast cancer were treated with intermediate-dose methotrexate (300 mg/m2) followed by 5-fluorouracil (600 mg/m2) and folinic acid-SF (Leucovorin) rescue (10 mg/m2 q 6 h x 6 doses) with or without tamoxifen (20 mg) and conjugated estrogen (Premarin) (.625 mg twice daily) depending on receptor status. There were two partial responses (8{\%}) with no difference in response between patients who did or did not receive hormones. Toxicity was primarily hematological and elevation of liver function tests. The above schedule has minimal activity in previously treated metastatic breast-cancer patients.",
author = "Swain, {S. M.} and S. Steinberg and Lippman, {Marc E}",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "11",
pages = "445--447",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer

AU - Swain, S. M.

AU - Steinberg, S.

AU - Lippman, Marc E

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Twenty-six patients (25 evaluable for response) with previously treated metastatic breast cancer were treated with intermediate-dose methotrexate (300 mg/m2) followed by 5-fluorouracil (600 mg/m2) and folinic acid-SF (Leucovorin) rescue (10 mg/m2 q 6 h x 6 doses) with or without tamoxifen (20 mg) and conjugated estrogen (Premarin) (.625 mg twice daily) depending on receptor status. There were two partial responses (8%) with no difference in response between patients who did or did not receive hormones. Toxicity was primarily hematological and elevation of liver function tests. The above schedule has minimal activity in previously treated metastatic breast-cancer patients.

AB - Twenty-six patients (25 evaluable for response) with previously treated metastatic breast cancer were treated with intermediate-dose methotrexate (300 mg/m2) followed by 5-fluorouracil (600 mg/m2) and folinic acid-SF (Leucovorin) rescue (10 mg/m2 q 6 h x 6 doses) with or without tamoxifen (20 mg) and conjugated estrogen (Premarin) (.625 mg twice daily) depending on receptor status. There were two partial responses (8%) with no difference in response between patients who did or did not receive hormones. Toxicity was primarily hematological and elevation of liver function tests. The above schedule has minimal activity in previously treated metastatic breast-cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0023764864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023764864&partnerID=8YFLogxK

M3 - Article

C2 - 3407622

AN - SCOPUS:0023764864

VL - 11

SP - 445

EP - 447

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -